Related Experiment Video

Updated: May 26, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate

Indira Elangovan1, Sivasakthivel Thirugnanam, Aoshuang Chen

  • 1Department of Biomedical Sciences, University of Illinois, College of Medicine, Rockford, IL 61107, USA.

Biochemical and Biophysical Research Communications
|December 31, 2011
PubMed

Insights

Silencing the receptor for advanced glycation end products (RAGE) using RNA interference inhibits prostate cancer cell growth and triggers apoptosis. This approach also reduced tumor growth in vivo, suggesting RAGE as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Receptor for advanced glycation end products (RAGE) is implicated in prostate cancer progression.
  • The therapeutic value of targeting RAGE in prostate cancer remains largely unexplored.

Purpose of the Study:

  • To investigate the therapeutic potential of silencing RAGE expression via RNA interference (RNAi) in prostate cancer.
  • To evaluate the in vitro and in vivo efficacy of RAGE-targeted RNAi.

Main Methods:

  • Utilized RNAi to downregulate RAGE expression in both androgen-dependent (LNCaP) and androgen-independent (DU-145) prostate cancer cell lines.
  • Assessed the impact of RAGE silencing on cell proliferation, apoptosis (caspase-8 and caspase-3 activation), and prostate-specific antigen (PSA) levels.
  • Administered RAGE RNAi constructs in a xenograft mouse model of prostate cancer to evaluate in vivo tumor growth inhibition.

Main Results:

  • RAGE downregulation via RNAi significantly inhibited proliferation in LNCaP and DU-145 prostate cancer cells.
  • Targeting RAGE induced apoptosis through the activation of caspase-8 and caspase-3 signaling pathways.
  • RAGE RNAi reduced PSA levels in LNCaP cells and suppressed tumor growth in vivo by modulating RAGE, HMGB1, and death receptor (DR4, DR5) expression.

Conclusions:

  • Silencing RAGE expression through RNAi demonstrates significant anti-proliferative and pro-apoptotic effects on prostate cancer cells.
  • RAGE-targeted RNAi therapy shows promise in inhibiting prostate cancer progression and tumor growth.
  • Targeting RAGE represents a potential novel therapeutic strategy for prostate cancer treatment.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy09:59

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...